3350 Stock Chart & Stats
€3.48
€0.38(12.10%)
At close: 4:00 PM EST
€3.48
€0.38(12.10%)
Day’s Range― - ―
52-Week Range€1.32 - €4.26
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€187.00M
Enterprise Value€173.90M
Total Cash (Recent Filing)€123.04M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Aug 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding53,783,330
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.99Price Target Upside100.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.12
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetWhitehawk’s balance sheet shows essentially no debt and positive equity of roughly $116M, which materially lowers interest-rate and refinancing risk. This provides a durable capital buffer to support clinical development and near-term IND milestones without immediate leverage pressure, preserving strategic optionality.
PIPE Financing Extends RunwayThe $87.5M PIPE materially extends cash runway and funds development of ADC programs, reducing short-term financing urgency. Significant insider and specialist participation signals stakeholder support, allowing management to prioritize clinical execution and IND filings rather than immediate capital raises, strengthening execution visibility.
Platform And Collaborations Broaden PipelineStrategic deals—an expanded CPT113 option set and a Biocytogen collaboration for bispecific ADC discovery—increase program optionality and pipeline breadth. Access to complementary discovery platforms and validated linkers enhances probability of differentiated candidates and supports multiple IND-readiness timelines across modalities.
Bears Say
Zero Trailing Revenue And Steep LossesWhitehawk reports zero TTM revenue while incurring roughly $116M in net losses, indicating an absence of recurring commercial cashflows to offset operating expenses. This structural revenue gap forces reliance on milestones or financings to sustain R&D and increases execution risk if clinical readouts or partner payments lag expectations.
Substantial Negative Free Cash FlowNegative FCF of about $108M TTM reflects heavy cash burn tied to clinical and development activities. Persistent outflows constrain flexibility to expand programs or weather delays, heightening dependency on external capital and increasing the chance of downscoped programs or milestone-driven pacing if cash generation does not improve.
Ongoing Reliance On External CapitalWhile the PIPE provides near-term runway, management’s repeated need for financing highlights structural funding dependence. Continued capital raises risk dilution, can divert management focus to financing, and could constrain strategic choices if subsequent markets or investor appetite tighten before meaningful clinical value is de‑risked.
Whitehawk Therapeutics News
3350 FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was €1.32 and its highest was €4.26 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is €187.00M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 31 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on May 07, 2026. The company reported -€0.28 earnings per share for the quarter, beating the consensus estimate of -€0.314 by €0.033.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 53,783,330 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -€0.28 in its last earnings report, beating expectations of -€0.314. Following the earnings report the stock price went down -1.734%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in DE:3350
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.99 (100.82% Upside)
€6.99 (100.82% Upside)
Insider Transactions
Sold Shares
Worth €1.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.54%
12-Months-Change
Fundamentals
Return on Equity
-79.63%
Trailing 12-Months
Asset Growth
-45.63%
Trailing 12-Months
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
3350 Stock 12 Month Forecast
Average Price Target
€6.99
▲(100.82% Upside)
Technical Analysis
Options Prices
Currently, No data available
---